Company Deep Dive
Read the full research report: business segments breakdown, earnings transcripts review, management credibility analysis, competitive landscape, and scenarios.
EXEL
Strong BuyFull HouseFLAGExelixis, Inc. · Healthcare · United States · $13.5B · Avg Vol: $146M/d
Although the company exhibits strong quality scores and upward EPS revisions, the record of insider selling triggers a mandatory flag under our hygiene rules.
COMPANY DESCRIPTION
Exelixis, Inc. is a biotechnology company focused on the discovery, development, and commercialization of innovative small molecule therapies for cancer. Its competitive strength stems from its flagship oncology product, CABOMETYX, and a robust pipeline targeting various cancer indications, establishing it as a significant player in the oncology therapeutics market.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.6B | 1.8B | 2.2B | 2.3B | 12.9% | 2.4B | 2.6B | 2.9B | 11.8% |
| EPS | 0.56 | 0.65 | 1.80 | 2.88 | 72.6% | 3.18 | 3.35 | 3.98 | 17.6% |
| Shares | 324.0M | 302.8M | 281.7M | 262.5M | -19.0% | 247.8M | — | — | — |
| Debt | 190.2M | 189.9M | 190.8M | 173.0M | -3.1% | 165.9M | — | — | — |
| Equity | 2.5B | 2.3B | 2.2B | 2.2B | -4.6% | — | — | — | — |
| Op CF | 362.6M | 333.3M | 700.0M | 884.3M | 34.6% | 1.2B | — | — | — |
| Inv CF | -524.4M | -27.0M | -116.8M | 350.4M | — | — | — | — | — |
| Fin CF | 0.6M | -546.1M | -628.8M | -969.6M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of EXEL are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| EXEL | Exelixis, Inc.(you) | $13.5B | 99 | Strong Buy |
| HALO | Halozyme Therapeutics, Inc. | $12.0B | 95 | Strong Buy |
| INCY | Incyte Corporation | $25.2B | 97 | Strong Buy |
| TECH | Bio-Techne Corporation | $11.3B | 76 | Buy |
| KRYS | Krystal Biotech, Inc. | $10.4B | 74 | Buy |
| CORT | Corcept Therapeutics Incorporated | $12.3B | 71 | Buy |
| ACAD | ACADIA Pharmaceuticals Inc. | $5.0B | 82 | Strong Buy |
| HRMY | Harmony Biosciences Holdings, Inc. | $2.3B | 100 | Strong Buy |
| BMRN | BioMarin Pharmaceutical Inc. | $12.5B | 63 | Hold |
| LGND | Ligand Pharmaceuticals Incorporated | $5.6B | 68 | Buy |
Peer medians: ROE -30.8% · P/E 27.1x · Gross margin 58.1%